Polyrizon Signs Non Binding LOI to Expand its Innovative Intranasal Drug Delivery Platform for Psychedelic-Based Treatments
March 14, 2025 08:35 ET | Source: Polyrizon Ltd. Raanana, Israel, March…
Polyrizon Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2024
March 11, 2025 16:27 ET | Source: Polyrizon Ltd. Raanana, Israel, March…
Polyrizon Announces Publication of U.S. National Patent Application for Its Innovative Hydrogel Nasal Technologies
Raanana, Israel, Dec. 30, 2024 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ)…
Blue Lake Biotechnology Reports Additional Promising Clinical Data from Ongoing Pediatric Clinical Study of Intranasal RSV Vaccine BLB201
Company leaders to speak today during the open public hearing session of…
